Serum CA 19-9 of Pancreatic Solid Mass Patients in Dr. Cipto Mangunkusumo National Central General Hospital

Kaka Renaldi, Adelia Nova Prahasary, Muhammad Hamdan Yuwaafi, Muhammad Maulana


Background: Pancreatic cancer is a lethal disease associated with poor prognosis. CA 19-9 is one of the elevated tumor markers in pancreatic cancer. However, data regarding CA 19-9 serum levels in pancreatic cancer in Indonesia is still scarce. This study aims to evaluate the clinical use of CA 19-9 in pancreatic cancer patients in Dr. Cipto Mangunkusumo National Central General Hospital.

Method: This study is a cross-sectional study that served data of demographic information, CA 19-9 level, TNM stage, site, histopathology, and resectability of pancreatic cancer. This study included 77 subjects. The data were collected from electronic medical records and registered data of patients in the Gastrointestinal Endoscopy Center, Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta between 2014 to 2019. Sensitivity and specificity analysis of CA 19-9 were performed using the ROC curve.

Results: We found 77 pancreatic cancer patients with a mean age of 54.2+10.4 years old. Most of them were males (59,7%), were found at stadium IV (41,6%) and unresectable tumor (68,8%). Non-adenocarcinoma which was mainly found in the head of the pancreas (76,6%) were confirmed in 67,5% of patients. The sensitivity and specificity of CA-19 9 to diagnose adenocarcinoma pancreas were 32% and 62% (p=0.939).

Conclusion: CA 19-9 should be used in aiding diagnosis, in conjunction with other modalities, such as radiological procedures and histopathology results. Measuring serum CA19-9 level in the early diagnosis could guide clinicians in determining the treatment and prognosis of pancreatic cancer.


CA-19 9; adenocarcinoma pancreas; bilirubin; resectability

Full Text:




  • There are currently no refbacks.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License